Willow Biosciences Stock Current Valuation
| WLLW Stock | CAD 0.07 0.01 6.25% |
Valuation analysis of Willow Biosciences helps investors to measure Willow Biosciences' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of the 11th of December 2024, Enterprise Value is likely to grow to about 14.8 M, while Enterprise Value Over EBITDA is likely to drop (1.09). Fundamental drivers impacting Willow Biosciences' valuation include:
Price Book 55.4632 | Enterprise Value 11.7 M | Enterprise Value Ebitda (332.50) | Price Sales 5.8779 | Forward PE 67.5676 |
Overvalued
Today
Please note that Willow Biosciences' price fluctuation is out of control at this time. Calculation of the real value of Willow Biosciences is based on 3 months time horizon. Increasing Willow Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Willow Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Willow Stock. However, Willow Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.075 | Real 0.0714 | Hype 0.08 | Naive 0.0757 |
The intrinsic value of Willow Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Willow Biosciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Willow Biosciences helps investors to forecast how Willow stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Willow Biosciences more accurately as focusing exclusively on Willow Biosciences' fundamentals will not take into account other important factors: Willow Biosciences Company Current Valuation Analysis
Willow Biosciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Willow Biosciences Current Valuation | 11.72 M |
Most of Willow Biosciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Willow Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Willow Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Willow Biosciences is extremely important. It helps to project a fair market value of Willow Stock properly, considering its historical fundamentals such as Current Valuation. Since Willow Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Willow Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Willow Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Willow Biosciences has a Current Valuation of 11.72 M. This is 99.92% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all Canada stocks is 99.93% higher than that of the company.
Willow Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Willow Biosciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Willow Biosciences could also be used in its relative valuation, which is a method of valuing Willow Biosciences by comparing valuation metrics of similar companies.Willow Biosciences is currently under evaluation in current valuation category among its peers.
Willow Fundamentals
| Return On Equity | -2.12 | ||||
| Return On Asset | -0.75 | ||||
| Operating Margin | (1.41) % | ||||
| Current Valuation | 11.72 M | ||||
| Shares Outstanding | 144.2 M | ||||
| Shares Owned By Insiders | 24.30 % | ||||
| Number Of Shares Shorted | 120.38 K | ||||
| Price To Earning | 4.00 X | ||||
| Price To Book | 55.46 X | ||||
| Price To Sales | 5.88 X | ||||
| Revenue | 1.17 M | ||||
| Gross Profit | 821 K | ||||
| EBITDA | (11.63 M) | ||||
| Net Income | (13.03 M) | ||||
| Cash And Equivalents | 11.01 M | ||||
| Cash Per Share | 0.19 X | ||||
| Total Debt | 2.16 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 16.20 X | ||||
| Book Value Per Share | 0.03 X | ||||
| Cash Flow From Operations | (10.92 M) | ||||
| Short Ratio | 0.09 X | ||||
| Earnings Per Share | (0.05) X | ||||
| Target Price | 2.0 | ||||
| Number Of Employees | 19 | ||||
| Beta | 1.14 | ||||
| Market Capitalization | 10.82 M | ||||
| Total Asset | 6.67 M | ||||
| Retained Earnings | (121.69 M) | ||||
| Working Capital | 2.36 M | ||||
| Net Asset | 6.67 M |
About Willow Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Willow Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Willow Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Willow Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Willow Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Willow Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Willow Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Willow Stock
| 0.82 | CMC | Cielo Waste Solutions Earnings Call This Week | PairCorr |
Moving against Willow Stock
The ability to find closely correlated positions to Willow Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Willow Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Willow Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Willow Biosciences to buy it.
The correlation of Willow Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Willow Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Willow Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Willow Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Willow Stock
Willow Biosciences financial ratios help investors to determine whether Willow Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Willow with respect to the benefits of owning Willow Biosciences security.